ALN-TTRSC04, Amvuttra 25 mg solution for injection in pre-filled syringe
ALN-TTRSC04-004
Phase 3 small_molecule active
Quick answer
ALN-TTRSC04, Amvuttra 25 mg solution for injection in pre-filled syringe for Hereditary transthyretin-mediated amyloidosis with polyneuropathy is a Phase 3 program (small_molecule) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alnylam Netherlands B.V.
- Indication
- Hereditary transthyretin-mediated amyloidosis with polyneuropathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active